Travere Therapeutics' Filspari boosts revenue with FDA approval, but heavy losses and competitive threats raise concerns for ...

When irbesartan therapy is discontinued, the dosage does not need to be tapered, regardless of the daily dose administered, because abrupt withdrawal of the drug is not associated with an increase ...

As recently as January this year the blood pressure medication Irbesartan Hydrochlorothiazide ... a blood-pressure generic, among fears that it contained the carcinogenic, N-Nitrosodimethylamine ...

Q4 2024 Earnings Call Transcript February 21, 2025 Operator: Good afternoon, and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call. Today’s call ...

The drug – already granted accelerated approval ... a maximally labelled dose of angiotensin 2 receptor antagonist irbesartan, a current standard of care. The company launched Filspari at ...

Travere Therapeutics reached an agreement Tuesday on what data the Food and Drug Administration would ... consistent proteinuria benefits versus irbesartan, we see a high probability of success ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

The drug had a 0.3mL favourable difference on the estimated glomerular filtration rate (eGFR) total slope and a 0.9mL annual favourable difference on the eGFR chronic slope compared with the control, ...

Say Manufacturers Ready To Bridge Impact Of GSK, Others Exit From Nigeria Nigerian Pharmaceutical companies are beginning to ...

ACPN Laments Poor Implementation Of Zero Duty On Drugs The surge in the cost of critical drugs for treatment and managing BP ...